Centre of Excellence for Cellular Therapy
Dr Denis Claude Roy and the Centre of Excellence for Cellular Therapy are pivotal in the development of Kiadis Pharma’s ATIR™. This is a novel immunotherapeutic strategy for 40% of patients who suffer from blood cancer and who do not have a standard of care stem cell donor available. ATIR™ enables hematopoietic stem cell transplantations using partially mismatched family members as donors to address this unmet medical need.
CellCAN's mission is to improve the quality, safety and feasibility of cell and gene therapy in Canada through optimal manufacturing practices.